Hot Features
プレミアム
Lipella Pharmaceuticals Inc (LIPO)
NASDAQ
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. 詳細を表示
PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with...
Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella...
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious...
PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S...
PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the...
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage biotechnology company addressing serious...
PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.2797 | 60.8970172001 | 0.4593 | 0.4675 | 0.3611 | 61046 | 0.4178952 | CS |
| 4 | 0.26 | 54.2797494781 | 0.479 | 0.575 | 0.3611 | 59168 | 0.47669928 | CS |
| 12 | 0.0014 | 0.189804772234 | 0.7376 | 0.788 | 0.3611 | 47360 | 0.56739499 | CS |
| 26 | -0.321 | -30.2830188679 | 1.06 | 1.3 | 0.3611 | 52585 | 0.71519754 | CS |
| 52 | -1.341 | -64.4711538462 | 2.08 | 2.71 | 0.3611 | 224989 | 1.90587248 | CS |
| 156 | -6.281 | -89.4729344729 | 7.02 | 7.72 | 0.3611 | 294908 | 2.48163216 | CS |
| 260 | -6.281 | -89.4729344729 | 7.02 | 7.72 | 0.3611 | 294908 | 2.48163216 | CS |
FALCON1
2日前
oldstocks
5月前
Muhbruh
5月前
Monksdream
5月前
oldstocks
5月前
Monksdream
5月前
crudeoil24
9月前
crudeoil24
9月前
Monksdream
9月前
Awl416
9月前
MiamiGent
1年前
TheFinalCD
1年前
81vette
1年前
81vette
1年前
81vette
1年前
81vette
1年前
81vette
1年前
81vette
1年前
MegaDeath
1年前
makinezmoney
1年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
